Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
miFzd4 is an experimental RNA interference (RNAi) tool, specifically a vector-based microRNA or short hairpin RNA (shRNA) designed to target and silence the expression of the human **Frizzled-4 (FZD4)** receptor. In the context of Crohn's disease research, it is utilized to investigate the role of the Wnt signaling pathway in mediating epithelial-mesenchymal transition (EMT) and subsequent intestinal fibrosis. By reducing FZD4 levels in intestinal epithelial cells, such as the HT29 line, miFzd4 has been shown to partially reverse the induction of mesenchymal markers (e.g., vimentin and snail1) and the activation of beta-catenin signaling triggered by IFNγ-treated macrophages. This suggests that the Wnt2b/FZD4 axis is a critical pathway in the pathogenesis of fibrostenotic Crohn's disease.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on miFzd4.